[go: up one dir, main page]

DE60322110D1 - Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten - Google Patents

Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten

Info

Publication number
DE60322110D1
DE60322110D1 DE60322110T DE60322110T DE60322110D1 DE 60322110 D1 DE60322110 D1 DE 60322110D1 DE 60322110 T DE60322110 T DE 60322110T DE 60322110 T DE60322110 T DE 60322110T DE 60322110 D1 DE60322110 D1 DE 60322110D1
Authority
DE
Germany
Prior art keywords
piperazin
piperidin
substituted
azntagonists
antagonistic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322110T
Other languages
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Boeck Benoit Christian Albe De
Joseph Elisabeth Leenaerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE60322110D1 publication Critical patent/DE60322110D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60322110T 2002-12-23 2003-12-17 Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten Expired - Lifetime DE60322110D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0214834 2002-12-23
PCT/EP2003/051043 WO2004056805A1 (en) 2002-12-23 2003-12-17 Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists

Publications (1)

Publication Number Publication Date
DE60322110D1 true DE60322110D1 (de) 2008-08-21

Family

ID=32668700

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322110T Expired - Lifetime DE60322110D1 (de) 2002-12-23 2003-12-17 Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten

Country Status (9)

Country Link
US (1) US7514424B2 (de)
EP (1) EP1578744B1 (de)
JP (1) JP4677235B2 (de)
AT (1) ATE400568T1 (de)
AU (1) AU2003298369B2 (de)
CA (1) CA2509090C (de)
DE (1) DE60322110D1 (de)
ES (1) ES2310260T3 (de)
WO (1) WO2004056805A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
ES2431524T3 (es) 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
EP1858896B1 (de) 2005-03-08 2010-08-18 Janssen Pharmaceutica NV Diazaspiro-[4,4]-nonanderivate als neurokinin-(nk1)-antagonisten
US20110152233A1 (en) * 2009-12-18 2011-06-23 Henner Knust Pyrrolidine compounds
WO2015200594A2 (en) 2014-06-25 2015-12-30 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
SI3297631T1 (sl) 2015-05-18 2019-12-31 Nerre Therapeutics Limited Antagonist NK-1/NK-3 receptorja za zdravljenje oblivov vročine
HUE065300T2 (hu) 2018-03-14 2024-05-28 Kandy Therapeutics Ltd Kettõs NK-1/NK-3 receptor antagonistákat tartalmazó új gyógyászati kiszerelés

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
AU7788500A (en) 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
FR2820426B1 (fr) * 2001-02-07 2007-05-11 Condat Sa Gel d'isolation thermique a reticulation controlee pour les lignes de transport d'hydrocarbures petroliers

Also Published As

Publication number Publication date
CA2509090C (en) 2012-01-24
EP1578744B1 (de) 2008-07-09
ES2310260T3 (es) 2009-01-01
JP2006512350A (ja) 2006-04-13
WO2004056805A1 (en) 2004-07-08
AU2003298369B2 (en) 2009-08-27
AU2003298369A1 (en) 2004-07-14
ATE400568T1 (de) 2008-07-15
US20060058285A1 (en) 2006-03-16
US7514424B2 (en) 2009-04-07
EP1578744A1 (de) 2005-09-28
JP4677235B2 (ja) 2011-04-27
CA2509090A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
SE0301700D0 (sv) Novel compounds
SE0101387D0 (sv) Novel compounds
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
TNSN07376A1 (en) Npy antagonists, preparation and use
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
MXPA05009063A (es) Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
TW200716628A (en) Novel compounds
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
WO2005032464A3 (en) Phenyl pyrrolidine ether tachykinin receptor antagonists
SE0401342D0 (sv) Therapeutic compounds
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE448777T1 (de) Mittel für die transdermale verabreichung von nikotin
UA84192C2 (en) Hydroisoindoline tachykinin receptor antagonists
DE60329330D1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
ATE537828T1 (de) Psychotropes mittel und nahrungsmittel zur förderung der gesundheit enthaltend neferin
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
DE60322110D1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten
WO2007002457A3 (en) Hydroisoindoline tachykinin receptor antagonists
SE0401968D0 (sv) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
MY130373A (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition